参考文献/References:
[1] Hamidi O,Young WF Jr,Iñiguez-Ariza NM,et al. Malignant pheochromocytoma and paraganglioma:272 patients over 55 years[J].J Clin Endocrinol Metab,2017,102(9):3296-3305.DOI:10.1210/jc.2017-00992.
[2] Lenders JW,Duh QY,Eisenhofer G,et al. Pheochromocytoma and paraganglioma:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2014,99(6):1915-1942.DOI:10.1210/jc.2014-1498.
[3] Dahia PL. Pheochromocytoma and paraganglioma pathogenesis:learning from genetic heterogeneity[J].Nat Rev Cancer,2014,14(2):108-119.DOI:10.1038/nrc3648.
[4] Buffet A,Morin A,Castro-Vega LJ,et al. Germline mutations in the mitochondrial 2-oxoglutarate/malate carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas[J].Cancer Res,2018,78(8):1914-1922.DOI:10.1158/0008-5472.CAN-17-2463.
[5] Remacha L,Comino-Méndez I,Richter S,et al. Targeted exome sequencing of krebs cycle genes reveals candidate cancer-predisposing mutations in pheochromocytomas and paragangliomas[J].Clin Cancer Res,2017,23(20):6315-6324.DOI:10.1158/1078-0432.CCR-16-2250.
[6] Remacha L,Currás-Freixes M,Torres-Ruiz R,et al. Gain-of-function mutations in DNMT3A in patients with paraganglioma[J].Genet Med,2018,20(12):1644-1651.DOI:10.1038/s41436-018-0003-y.
[7] Remacha L,Pirman D,Mahoney CE,et al. Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas[J].Am J Hum Genet,2019,104(4):651-664.DOI:10.1016/j.ajhg.2019.02.017.
[8] Fishbein L,Leshchiner I,Walter V,et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma[J].Cancer Cell,2017,31(2):181-193.DOI:10.1016/j.ccell.2017.01.001.
[9] Heaphy CM,De Wilde RF,Jiao YC,et al. Altered telomeres in tumors with ATRX and DAXX mutations[J].Science,2011,333(6041):425.DOI:10.1126/science.1207313.
[10] Juhlin CC,Stenman A,Haglund F,et al. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene[J].Genes Chromosomes Cancer,2015,54(9):542-554.DOI:10.1002/gcc.22267.
[11] Fishbein L,Leshchiner I,Walter V,et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma[J].Cancer Cell,2017,31(2):181-193.DOI:10.1016/j.ccell.2017.01.001.
[12] Castro-Vega LJ,Letouzé E,Burnichon N,et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas[J].Nat Commun,2015,6:6044.DOI:10.1038/ncomms7044.
[13] Morin A,Goncalves J,Moog S,et al. TET-mediated hypermethylation primes SDH-deficient cells for HIF2α-driven mesenchymal transition[J].Cell Rep,2020,30(13):4551-4566.e7.DOI:10.1016/j.celrep.2020.03.022.
[14] Björklund P,Backman S. Epigenetics of pheochromocytoma and paraganglioma[J].Mol Cell Endocrinol,2018,469:92-97.DOI:10.1016/j.mce.2017.06.016.
[15] Bernardo-Castiñeira C,Valdés N,Celada L,et al. Epigenetic deregulation of protocadherin PCDHGC3 in pheochromocytomas/paragangliomas associated with SDHB mutations[J].J Clin Endocrinol Metab,2019,104(11):5673-5692.DOI:10.1210/jc.2018-01471.
[16] Yu A,Li M,Xing C,et al. A comprehensive analysis identified the key differentially expressed circular ribonucleic acids and methylation-related function in pheochromocytomas and paragangliomas[J].Front Genet,2020,11:15.DOI:10.3389/fgene.2020.00015.
[17] Neumann HPH,Young WF Jr,Eng C. Pheochromocytoma and paraganglioma[J].N Engl J Med,2019,381(6):552-565.DOI:10.1056/NEJMra1806651.
[18] 王芬,童安莉,曾正陪. 恶性嗜铬细胞瘤/副神经节瘤的治疗[J].国际内分泌代谢杂志,2016,36(3):187-190.DOI:10.3760/cma.j.issn.1673-4157.2016.03.11.
相似文献/References:
[1]刘鹭,高莹,张俊清,等.甲氧基肾上腺素类物质、3-甲氧酪胺及嗜铬粒蛋白A在PPGL诊断中的作用[J].国际内分泌代谢杂志,2021,41(02):96.[doi:10.3760/cma.j.cn12383-20200522-05070]
Liu Lu,Gao Ying,Zhang Junqing,et al.Role of metanephrines, 3-methoxytyramine and chromogranin A in the diagnosis of PPGL[J].International Journal of Endocrinology and Metabolism,2021,41(02):96.[doi:10.3760/cma.j.cn12383-20200522-05070]
[2]张越,周波.巨大囊性嗜铬细胞瘤/副神经节瘤诊治研究进展[J].国际内分泌代谢杂志,2021,41(03):212.[doi:10.3760/cma.j.cn121383-20200922-09042]
Zhang Yue,Zhou Bo..Research progress on diagnosis and treatment of giant cystic pheochromocytoma/paraganglioma[J].International Journal of Endocrinology and Metabolism,2021,41(02):212.[doi:10.3760/cma.j.cn121383-20200922-09042]
[3]刘海春 高洪波 李赟 李隆敏 邵玉军.基因突变对嗜铬细胞瘤/副神经节瘤临床特征及预后的影响[J].国际内分泌代谢杂志,2023,43(05):392.[doi:10.3760/cma.j.cn121383-20221029-10044]
Liu Haichun,Gao Hongbo,Li Yun,et al.Effect of gene mutations on clinical features and prognosis of pheochromocytoma/paraganglioma[J].International Journal of Endocrinology and Metabolism,2023,43(02):392.[doi:10.3760/cma.j.cn121383-20221029-10044]